Skip to main content

NICHOS INMUNOMODULATORIOS RADIO-ACTIVADOS

AC21_2/00046

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Programación Conjunta Internacional
Call year 2021
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION SANITARIA DE SANTIAGO DE COMPOSTELA
Execution centre CENTRO SINGULAR DE INVESTIGACION EN MEDICINA MOLECULAR Y ENFERMEDADES CRONICAS (CIMUS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Viral protein-based nanoparticles (part 2): Pharmaceutical applications

  • Mellid-Carballal, Rocio
  • Gutierrez-Gutierrez, Sara
  • Rivas, Carmen
  • Garcia-Fuentes, Marcos
Viral protein nanoparticles (ViP NPs) such as virus-like particles and virosomes are structures halfway between viruses and synthetic nanoparticles. The biological nature of ViP NPs endows them with the biocompatibility, biodegradability, and functional properties that many synthetic nanoparticles lack. At the same time, the absence of a viral genome avoids the safety concerns of viruses. Such characteristics of ViP NPs offer a myriad of opportunities for theirapplication at several points across disease development: from prophylaxis to diagnosis and treatment. ViP NPs present remarkable immunostimulant properties, and thus the vaccination field has benefited the most from these platforms capable of overcoming the limitations of both traditional and subunit vaccines. This was reflected in the marketing authorization of several VLP- and virosome-based vaccines. Besides, ViP NPs inherit the ability of viruses to deliver their cargo to target cells. Because of that, ViP NPs are promising candidates as vectors for drug and gene delivery, and for diagnostic applications. In this review, we analyze the pharmaceutical applications of ViP NPs, describing the products that are commercially available or under clinical evaluation, but also the advances that scientists are making toward the implementation of ViP NPs in other areas of major pharmaceutical interest., This publication is part of the following grants: PID2021–124986OB-I00 (Project “IMMMA”) funded by MCIN/AEI/ 10.13039/ 501100011033 and by “ERDF A way of making Europe”; AC21_2/00046 (Project “RAIN”) funded by Health Institute Carlos III/MCIN/AEI/ 10.13039/501100011033 and by “European Union NextGenerationEU/EURONANOMED 3; PID2021–126510NB-I00 funded by MCIN/AEI/ 10.13039/501100011033 and “ERDF A way of making Europe”; and ED431G 2019/02 grant funded by Xunta de Galicia. RMC is a recipient of a predoctoral grant from the Ministerio de Educación y FormaciónProfesional (FPU20/01525)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Viral protein nanoparticles (Part 1): Pharmaceutical characteristics

  • Mellid-Carballal, Rocio
  • Gutierrez-Gutierrez, Sara
  • Rivas, Carmen
  • Garcia-Fuentes, Marcos
Viral protein nanoparticles fill the gap between viruses and synthetic nanoparticles. Combining advantageous properties of both systems, they have revolutionized pharmaceutical research. Virus-like particles are characterized by a structure identical to viruses but lacking genetic material. Another type of viral protein nanoparticles, virosomes, are similar to liposomes but include viral spike proteins. Both systems are effective and safe vaccine candidates capable of overcoming the disadvantages of both traditional and subunit vaccines. Besides, their particulate structure, biocompatibility, and biodegradability make them good candidates as vectors for drug and gene delivery, and for diagnostic applications. In this review, we analyze viral protein nanoparticles from a pharmaceutical perspective and examine current research focused on their development process, from production to administration. Advances in synthesis, modification and formulation of viral protein nanoparticles are critical so that large-scale production of viral protein nanoparticle products becomes viable and affordable, which ultimately will increase their market penetration in the future. We will discuss their expression systems, modification strategies, formulation, biopharmaceutical properties, and biocompatibility., This publication is part of the following grants: PID2021–124986OB-I00 (Project “IMMMA”) funded by MCIN/AEI/ 10.13039/ 501100011033 and by “ERDF A way of making Europe”; AC21_2/00046 (Project “RAIN”) funded by Health Institute Carlos III/MCIN/AEI/ 10.13039/501100011033 and by “European Union NextGenerationEU/ EURONANOMED 3. Funding at the laboratory of CR is provided by PID2021–126510NB-I00 funded by MCIN/AEI/10.13039/ 501100011033 and FEDER (a way to build Europe), and by Xunta de Galicia (ED431G 2019/02). RMC is a recipient of a predoctoral grant from the Ministerio de Educación y Formación Profesional (FPU20/01525)., Peer reviewed